z-logo
open-access-imgOpen Access
Plaque Evaluation by Ultrasound and Transcriptomics Reveals BCLAF1 as a Regulator of Smooth Muscle Cell Lipid Transdifferentiation in Atherosclerosis
Author(s) -
Urszula Rykaczewska,
Quanyi Zhao,
Peter SalibaGustafsson,
Mariette Lengquist,
Malin Kronqvist,
Otto Bergman,
Zhiqiang Huang,
Kent Lund,
Katarina Wadén,
Zara Pons Vila,
Kenneth Caidahl,
Josefin Skogsberg,
Vladana Vukojević,
J. Lindeman,
Joy Roy,
Göran K. Hansson,
Eckardt Treuter,
Nicholas J. Leeper,
Per Eriksson,
Ewa Ehrenborg,
Anton Razuvaev,
Ulf Hedin,
Ljubica Matic
Publication year - 2022
Publication title -
arteriosclerosis thrombosis and vascular biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.007
H-Index - 270
eISSN - 1524-4636
pISSN - 1079-5642
DOI - 10.1161/atvbaha.121.317018
Subject(s) - biology , downregulation and upregulation , gene silencing , cd68 , transcriptome , transdifferentiation , cancer research , gene expression , immunology , immunohistochemistry , cell , genetics , gene
Background: Understanding the processes behind carotid plaque instability is necessary to develop methods for identification of patients and lesions with stroke risk. Here, we investigated molecular signatures in human plaques stratified by echogenicity as assessed by duplex ultrasound. Methods: Lesion echogenicity was correlated to microarray gene expression profiles from carotid endarterectomies (n=96). The findings were extended into studies of human and mouse atherosclerotic lesions in situ, followed by functional investigations in vitro in human carotid smooth muscle cells (SMCs). Results: Pathway analyses highlighted muscle differentiation, iron homeostasis, calcification, matrix organization, cell survival balance, andBCLAF1 (BCL2 [B-cell lymphoma 2]-associated transcription factor 1) as the most significant signatures.BCLAF1 was downregulated in echolucent plaques, positively correlated to proliferation and negatively to apoptosis. By immunohistochemistry, BCLAF1 was found in normal medial SMCs. It was repressed early during atherogenesis but reappeared in CD68+ cells in advanced plaques and interacted with BCL2 by proximity ligation assay. In cultured SMCs,BCLAF1 was induced by differentiation factors and mitogens and suppressed by macrophage-conditioned medium.BCLAF1 silencing led to downregulation of BCL2 and SMC markers, reduced proliferation, and increased apoptosis. Transdifferentiation of SMCs by oxLDL (oxidized low-denisty lipoprotein) was accompanied by upregulation of BCLAF1, CD36, and CD68, while oxLDL exposure withBCLAF1 silencing preserved MYH (myosin heavy chain) 11 expression and prevented transdifferentiation.BCLAF1 was associated with expression of cell differentiation, contractility, viability, and inflammatory genes, as well as the scavenger receptorsCD36 andCD68 . BCLAF1 expression in CD68+/BCL2+ cells of SMC origin was verified in plaques from MYH11 lineage-tracing atherosclerotic mice. Moreover,BCLAF1 downregulation associated with vulnerability parameters and cardiovascular risk in patients with carotid atherosclerosis.Conclusions: Plaque echogenicity correlated with enrichment of distinct molecular pathways and identifiedBCLAF1 , previously not described in atherosclerosis, as the most significant gene. Functionally, BCLAF1 seems necessary for survival and transdifferentiation of SMCs into a macrophage-like phenotype. The role of BCLAF1 in plaque vulnerability should be further evaluated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom